Monday Lecture Series
(open to the Rockefeller community)
Monday, April 25, 2022
Thomas Tuschl, Ph.D.
Professor,
Head of the Laboratory of RNA Molecular Biology,
The Rockefeller University
First-in-class non-covalent allosteric small-molecule inhibitors of SARS-CoV NSP14 methyltransferase
Recommended Readings:
Empirical Articles
Wang, X., Sacramento, C. Q., Jockusch, S., Chaves, O. A., Tao, C., Fintelman-Rodrigues, N., Chien, M., Temerozo, J. R., Li, X., Kumar, S., Xie, W., Patel, D. J., Meyer, C., Garzia, A., Tuschl, T., Bozza, P. T., Russo, J. J., Souza, T., & Ju, J. (2022). Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. Communications biology, 5(1), 154.
La Rocca, G., King, B., Shui, B., Li, X., Zhang, M., Akat, K. M., Ogrodowski, P., Mastroleo, C., Chen, K., Cavalieri, V., Ma, Y., Anelli, V., Betel, D., Vidigal, J., Tuschl, T., Meister, G., Thompson, C. B., Lindsten, T., Haigis, K., & Ventura, A. (2021). Inducible and reversible inhibition of miRNA-mediated gene repression in vivo. eLife, 10, e70948
Garzia, A., Meyer, C., & Tuschl, T. (2021). The E3 ubiquitin ligase RNF10 modifies 40S ribosomal subunits of ribosomes compromised in translation. Cell reports, 36(5), 109468.
Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, Da Silva APD, Dias SDSG, da Silva CDS, Ferreira AC, Mattos M, Pão CRR, de Freitas CS, Soares VC, Hoelz LVB, Fernandes TVA, Branco FSC, Bastos MM, Boechat N, Saraiva FB, Ferreira MA, Jockusch S, Wang X, Tao C, Chien M, Xie W, Patel D, Garzia A, Tuschl T, Russo JJ, Rajoli RKR, Pedrosa CSG, Vitória G, Souza LRQ, Goto-Silva L, Guimarães MZ, Rehen SK, Owen A, Bozza FA, Bou-Habib DC, Ju J, Bozza PT, Souza TML. (2021). In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. J Antimicrob Chemother, 76(7):1874-1885.
